Skip to main content

B7-H3.CD28Z.CART

B7-H3.CD28Z.CART in CNS Neoplasms

  • RegistryNCT07390539
  • PhasePhase 1
  • StatusRecruiting
  • ConditionCentral Nervous System Neoplasms
  • SponsorRobbie Majzner
How B7-H3.CD28Z.CART worksNCT073905391 min

What the film says

Read the transcript

Medulloblastoma and its cousins are the most common malignant brain tumors of childhood. When they return after treatment, there is no reliable cure.

The idea: send engineered immune cells first through the blood, then directly into the fluid around the brain.

Most of these tumors carry a surface protein called B7-H3. A child's own T cells are fitted with a receptor for it, and after chemotherapy makes room, given once by vein. Then, through a small reservoir under the scalp, further doses go into the ventricles every four weeks, up to eight, reaching tumor spread along the brain and spine.

A new trial, at Dana-Farber and Boston Children's, ages two to twenty-one. Susan Chi leads it. Safety first. Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT07390539

    Medulloblastoma most common malignant pediatric brain tumor; recurrence has no reliable cure; B7-H3 over-expressed on many tumors; IV infusion on day 0 after Flu/Cy, then intracerebroventricular doses every 28 days up to 8 total; Reservoir under the scalp (Ommaya) (+2 more lines)

The drug

What is being tested.

Autologous CAR T cells targeting B7-H3 (CD276), administered intravenously (into the vein) per protocol.

Lymphodepleting chemotherapy administered intravenously per institutional standards.

This is a single-institution, Phase 1/1b, open-label study to test the safety and effectiveness of a cell therapy at different doses for children and young adults with recurrent or progressive brain tumors. Recurrent/recurred means a tumor that has gone away and then came back. This cell therapy is called B7- H3.CD28Z.CART, referred to as B7-H3 CAR T cells. B7-H3 is a protein that is over-expressed on many tumor cells, making it a good target for cancer cell therapy. The U.S.

The study

How the trial runs.

The purpose of this research study is to test the safety and effectiveness of a cell therapy at different doses for children and young adults with recurrent or progressive brain tumors.

The names of the study investigational therapies involved in this study are: * Fludarabine (a type of chemotherapy) * Cyclophosphamide (a type of chemotherapy) * B7-H3 CAR T cells (a type of cellular therapy)

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Pre-screening Inclusion Criteria:
  • Participants must have histologically and/or molecularly confirmed CNS embryonal tumor (see eligible tumor types below), OR ependymoma that is recurrent/progressive following standard of care treatment.
  • -Eligible CNS embryonal tumor types include:
  • Atypical Teratoid Rhabdoid Tumor (ATRT)
  • Embryonal Tumor with Multilayered Rosettes (ETMR) Pineoblastoma
  • Other CNS embryonal tumor types, at the discretion of the study chair (or designee)

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.